eCite Digital Repository

Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data


Chen, J and Taylor, BV and Blizzard, L and Simpson Jr, S and Palmer, AJ and van der Mei, IAF, Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data, Journal of Neurology, Neurosurgery and Psychiatry, 89, (11) pp. 1200-1207. ISSN 0022-3050 (2018) [Refereed Article]

Copyright Statement

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018.

DOI: doi:10.1136/jnnp-2018-318228


Background: The direct comparative evidence on treatment effects of available multiple sclerosis (MS) disease-modifying therapies (DMTs) is limited, and few studies have examined the benefits of DMTs on employment outcomes. We compared the effects of DMTs used in the previous 5 years on improving the work attendance, amount of work and work productivity of people with MS.

Methods: The Australian MS Longitudinal Study collected data from participants on DMTs usage from 2010 to 2015 and whether DMTs contributed to changes in employment outcomes. We classified 11 DMTs into three categories based on their clinical efficacy (β-interferons and glatiramer acetate as category 1; teriflunomide and dimethyl fumarate as category 2; fingolimod, natalizumab, alemtuzumab and mitoxantrone as category 3). Each DMT used by a participant was treated as one observation and analysed by log-multinomial regression.

Results: Of the 874 participants included, 1384 observations were generated. Those who used category 3 (higher efficacy) DMTs were 2-3 times more likely to report improvements in amount of work, work attendance and work productivity compared with those who used category 1 (classical injectable) DMTs. Natalizumab was associated with superior beneficial effects on patient-reported employment outcomes than fingolimod (RR=1.76, 95% CI 1.02 to 3.03 for increased work attendance and RR=1.46, 95% CI 1.02 to 2.10 for increased work productivity).

Conclusions: Those using the higher efficacy (category 3) DMTs, particularly fingolimod and natalizumab, reported significant increases in amount of work, work attendance and work productivity, suggesting they have important beneficial effects on work life in people with MS.

Item Details

Item Type:Refereed Article
Keywords:disease-modifying therapy, employment, fingolimod, multiple sclerosis, natalizumab
Research Division:Biomedical and Clinical Sciences
Research Group:Neurosciences
Research Field:Central nervous system
Objective Division:Health
Objective Group:Clinical health
Objective Field:Clinical health not elsewhere classified
UTAS Author:Chen, J (Miss Jing Chen)
UTAS Author:Taylor, BV (Professor Bruce Taylor)
UTAS Author:Blizzard, L (Professor Leigh Blizzard)
UTAS Author:Simpson Jr, S (Dr Steve Simpson JR)
UTAS Author:Palmer, AJ (Professor Andrew Palmer)
UTAS Author:van der Mei, IAF (Professor Ingrid van der Mei)
ID Code:126955
Year Published:2018
Web of Science® Times Cited:2
Deposited By:Menzies Institute for Medical Research
Deposited On:2018-07-04
Last Modified:2019-04-29

Repository Staff Only: item control page